AlphAIalphai — Financial news for AI agents
stocktitan.netSEP 21 min read$JNJ

$9.2M J&J (NYSE: JNJ) stock sale planned for 2026

Timothy Schmid plans to sell 33,597 shares of Johnson & Johnson (JNJ) common stock, valued at $9.23 million, under Rule 144. The sale is scheduled for September 2, 2026, and the shares will be issued from a stock option exercise with the company, settled in cash.

Original reporting
stocktitan.net
Published Sep 2, 2026, 3:27 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 2, 2026, 4:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefFinancial news
Primary signal
$JNJ
Neutral
medium confidence
Mentioned
$JNJ
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The filing informs investors of upcoming share supply but is unlikely to move the stock significantly.

02

Market read

A routine insider sale with modest dollar value; limited trading relevance.

03

What to watch

Potential tax planning or diversification motives unrelated to company fundamentals.

Relevance 4/10Novelty 4/10Timing: Sep 2 2026 (sale date)

Background

Form 144 filings disclose planned insider sales under Rule 144, providing transparency to the market.

Company-level read

Ticker impact

$JNJNeutralMedium confidence
Context

Timothy Schmid filed a Form 144 to sell 33,597 J&J shares worth about $9.23 million on Sep 2 2026.

Expected impact

Small dip or flat price action expected.

Evidence & confidence

The sale size is modest relative to JNJ's market cap; impact limited to short‑term supply side.

Market effects

Sector

Minimal effect on healthcare sector.

Regional

None.

Global

None.

Counterpoint

What could challenge this read

Insider sale may signal confidence in stock stability despite the sell‑off.

Key entities

  • Insider
    Timothy Schmid

    Executive/officer of Johnson & Johnson selling shares.

  • Company
    Johnson & Johnson

    Healthcare conglomerate (ticker JNJ).

Read at source← All news

Related articles

SEP 3
$JNJMedAI 8/10

J&J Gains as AbbVie Posts 74% Myeloma Response

J&J shares rose 1% to $277.955. AbbVie's experimental myeloma drug showed 74% response rate, 60% risk reduction. J&J's Carvykti drove 6.8% operational growth in Q2. Reuters notes AbbVie's drug complements, not replaces, J&J's treatment. J&J's stock is 44.08% above GF Value estimate.

tradingview.com2 min
SEP 2
$JNJMed

U.S. FDA warning prompts Taiwan red alert over heart pump device

Taiwan's FDA issued a red alert over a heart pump device after the U.S. FDA warned of a defect in Abiomed Inc.'s Automated Impella Controllers, linked to 3 deaths and 37 injuries. The device, used in 19 Taiwanese hospitals, is being recalled for a cartridge recognition issue. Johnson & Johnson MedTech, the local license holder, must notify providers and implement fixes.

focustaiwan.tw2 min
AUG 31
$JNJHighAI 8/10

Johnson & Johnson cuts 2026, 2027 adjusted EPS guidance by up to $1.36

Johnson & Johnson revised its 2026 and 2027 adjusted EPS guidance downward, citing expected decreases in operational and adjusted metrics. For 2026, EPS is expected to decrease by $0.64, and for 2027, by $1.36. The company also announced a $5.5 billion settlement for talc-related claims, with the first payment of up to $3 billion due in 2027.

scanx.trade2 min
AUG 31
$JNJMedAI 8/10

Johnson & Johnson names Tom Cavanaugh as Innovative Medicine chairman

Johnson & Johnson (JNJ) appointed Tom Cavanaugh as Executive Vice President and Worldwide Chairman of its Innovative Medicine division, effective September 1, 2026. Cavanaugh succeeds Jennifer Taubert, who is retiring after 21 years. The division generated over $60 billion in annual revenue under Taubert's leadership. JNJ's shares rose 0.86% to $258.03 on Friday following two biotech acquisitions: a $1 billion cash deal for Firefly Bio and a $2.58 billion option to acquire Sail Biomedicines, whi

scanx.trade3 min